Advantage Austria Show navigation
We think you are in the USAGo to this country pageChange country

2016 Export Awards winners: Boehringer Ingelheim


Since 1994 the Austrian Federal Economic Chamber and the Austrian Federal Ministry of Science, Research and Economy have been presenting Export Awards to Austrian companies for their exceptional success on international markets. The special ‘Foreign Investor of the Year’ award, presented for the first time this year, went to Boehringer Ingelheim RCV GmbH & Co KG.

Boehringer Ingelheim will invest more than half a billion Euro at its Vienna site over the next five years, creating at least 400 new jobs. Establishing a new large-scale biopharmaceutical production facility using cell cultures in Vienna will be the largest single investment ever made by Boehringer Ingelheim. The research-driven company has made several investments in the Austrian capital: in 2015 a research building with a EUR 20 million investment was inaugurated, where 80 experts work on new therapies in the field of immuno-oncology. Currently a new building for the Research Institute of Molecular Pathology is being built by Boehringer Ingelheim RCV at a cost of around EUR 50 million..

The family-owned company was founded in 1885 and is now one of the world’s top 20 pharmaceutical companies. The Austrian subsidiary of the international group, founded in 1948 in a pharmacy in Vienna, was Boehringer Ingelheim's first foreign company. From it's modest beginnings it has developed to become a modern high-technology company with 1,470 employees. The Boehringer Ingelheim Regional Center Vienna (RCV) is responsible for the company's pharmaceutical business in Austria and more than 30 other countries in Central and Eastern Europe, Central Asia and Israel. Vienna is the international oncology research centre as well as a location for biopharmaceutical R & D and manufacturing.

Boehringer Ingelheim is the very first company to win the special ‘Foreign Investor of the Year‘ award.